+1803294983432
customer.service@microbix.com
Respiratory Viral and Bacterial External Quality Controls
In vitro diagnostic (IVD) and research use only (RUO) bacterial and respiratory viral controls for nucleic acid and antigen detection assays.
Setting the Gold Standard for Infectious Disease Diagnostic Standards
Ready to Use External Quality Controls
Microbix is the only supplier licensed to manufacture External Quality Controls using Copan’s FLOQSwab® . These controls are room-temperature stable and offer a 2-year shelf life from the date of manufacture when stored at 2–30 °C.
Global Manufacturing Excellence
Microbix External Quality Controls are manufactured under the strict requirements of ISO 13485:2016. Microbix’s IVD External Quality Controls are registered as Class I medical devices with the U.S. FDA and Health Canada. Certain IVD products are also CE-IVD registered and hold Australian TGA registration.
Unique Diagnostics Solutions
Microbix offers inactivated multiplex SARS-CoV-2/FluA&B/RSV positive swabs that mimic patient specimen formats. Multiple levels of single-analyte SARS-CoV-2, RSV, Influenza A, and Influenza B swab products are also available.
Download Our Full Product Brochure
Respiratory Viral and Bacterial Products
| Product Name | REDx™ (IVD) Catalogue Number |
PROCEEDx™ (RUO) Catalogue Number |
|
| VIRAL | |||
| Single-Target Products | |||
| Adenovirus Positive | N/A | VP-15-01 | Request Quote |
| Enterovirus Positive | RED-148-01* | VP-148-01 | Request Quote |
| Enterovirus Positive Swab | RED-S-148-01* | VP-S-148-01 | Request Quote |
| Human Metapneumovirus Positive | RED-146-01* | VP-146-01 | Request Quote |
| Human Metapneumovirus Positive Swab | RED-S-146-01* | VP-S-146-01 | Request Quote |
| Influenza A Positive | RED-13-01* | VP-13-01 | Request Quote |
| Influenza A Positive (MDx) | N/A | VP-13-M1L | Request Quote |
| Influenza A Positive Swab | RED-S-13-01* | VP-S-13-01 | Request Quote |
| Influenza A Positive Swab *Formulated with human cells |
RED-S-13-M1* | VP-S-13-M1 | Request Quote |
| Influenza A Positive Swab (Low Level) *Formulated with human cells |
RED-S-13-M1L* | VP-S-13-M1L | Request Quote |
| Influenza A Positive Swab (Ultra Low) *Formulated with human cells |
N/A | VP-S-13-L1 | Request Quote |
| Influenza B Positive | RED-14-01* | VP-14-01 | Request Quote |
| Influenza B Positive (MDx) | N/A | VP-14-M1L | Request Quote |
| Influenza B Positive Swab | RED-S-14-01* | VP-S-14-01 | Request Quote |
| Influenza B Positive Swab *Formulated with human cells |
RED-S-14-M1* | VP-S-14-M1 | Request Quote |
| Influenza B Positive Swab (Low Level) *Formulated with human cells |
RED-S-14-M1L* | VP-S-14-M1L | Request Quote |
| Influenza B Positive Swab (Ultra Low) *Formulated with human cells |
N/A | VP-S-14-L1 | Request Quote |
| Parainfluenza 3 Virus Positive | N/A | VP-10-M1 | Request Quote |
| Respiratory Syncytial Virus Positive | RED-07-01* | VP-07-01 | Request Quote |
| Respiratory Syncytial Virus Positive (MDx) | N/A | VP-07-M1L | Request Quote |
| Respiratory Syncytial Virus Positive Swab | RED-S-07-01* | VP-S-07-01 | Request Quote |
| Respiratory Syncytial Virus Positive Swab *Formulated with human cells |
RED-S-07-M1* | VP-S-07-M1 | Request Quote |
| Respiratory Syncytial Virus Positive Swab (Low Level) *Formulated with human cells |
RED-S-07-M1L* | VP-S-07-M1L | Request Quote |
| Respiratory Syncytial Virus Positive Swab (Ultra Low) *Formulated with human cells |
N/A | VP-S-07-L1 | Request Quote |
| Rhinovirus Positive | RED-147-01* | VP-147-01 | Request Quote |
| Rhinovirus Positive Swab | RED-S-147-01* | VP-S-147-01 | Request Quote |
| SARS-CoV-2 Positive | RED-19-01 | VP-19-01 | Request Quote |
| SARS-CoV-2 Positive Swab *Formulated with human cells |
RED-S-19-01 | VP-S-19-01 | Request Quote |
| SARS-CoV-2 Positive Swab (Ultra Low) *Formulated with human cells |
N/A | VP-S-19-L1 | Request Quote |
| SARS-CoV-2 Ag Positive Swab | RED-S-19-02 | VP-S-19-02 | Request Quote |
| SARS-CoV-2 B.1.1.7 Positive Swab | RED-S-19-03 | VP-S-19-03 | Request Quote |
| SARS-CoV-2 B.1.351 Positive Swab | RED-S-19-04 | VP-S-19-04 | Request Quote |
| SARS-CoV-2 P.1 Positive Swab | RED-S-19-05 | VP-S-19-05 | Request Quote |
| SARS-CoV-2 B.1.617 Positive Swab | RED-S-19-06 | VP-S-19-06 | Request Quote |
| SARS-CoV-2 B.1.1.529 Positive Swab | RED-S-19-07 | VP-S-19-07 | Request Quote |
| Seasonal coronavirus NL63 Positive | RED-149-01* | VP-149-01 | Request Quote |
| Seasonal coronavirus NL63 Positive Swab | RED-S-149-01* | VP-S-149-01 | Request Quote |
| Multi-Target Products | |||
| Adenovirus and Rotavirus Positive | N/A | VP-15-02 | Request Quote |
| Influenza A and Influenza B Positive | RED-13-02* | VP-13-02 | Request Quote |
| Influenza A and RSV Positive | N/A | VP-13-03 | Request Quote |
| Influenza A and Adenovirus Positive | N/A | VP-13-04 | Request Quote |
| Influenza A and Rotavirus Positive | N/A | VP-13-05 | Request Quote |
| Influenza B and RSV Positive | N/A | VP-14-02 | Request Quote |
| Influenza B and Adenovirus Positive | N/A | VP-14-03 | Request Quote |
| Influenza B and Rotavirus Positive | N/A | VP-14-04 | Request Quote |
| Respiratory NAAT Influenza A and Influenza B Positive Swab | RED-S-13-M2* | VP-S-13-M2 | Request Quote |
| Respiratory NAAT Influenza A and RSV Positive Swab | RED-S-13-M3* | VP-S-13-M3 | Request Quote |
| Respiratory NAAT Influenza A and SARS-CoV-2 Positive Swab | RED-S-13-M4* | VP-S-13-M4 | Request Quote |
| Respiratory NAAT Influenza B and RSV Positive Swab | RED-S-14-M2* | VP-S-14-M2 | Request Quote |
| Respiratory NAAT Influenza B and SARS-CoV-2 Positive Swab | RED-S-14-M3* | VP-S-14-M3 | Request Quote |
| Respiratory NAAT RSV and SARS-CoV-2 Positive Swab | RED-S-07-M2* | VP-S-07-M2 | Request Quote |
| Respiratory Viral Panel 1 Positive *Formulated with Human metapneumovirus, Enterovirus, Rhinovirus and Seasonal coronavirus NL63 |
RED-145-M1* | VP-145-M1 | Request Quote |
| Respiratory Viral Panel 1 Positive Swab *Formulated with Human metapneumovirus, Enterovirus, Rhinovirus and Seasonal coronavirus NL63 |
RED-S-145-M1* | VP-S-145-M1 | Request Quote |
| SARS-CoV-2/FluA&B/RSV Positive Swab | RED-S-19-M1 | VP-S-19-M1 | Request Quote |
| BACTERIAL | |||
| Single-Target Products | |||
| Group A Strep Positive Swab (High Level) | RED-S-70-01* | VP-S-70-01 | Request Quote |
| Group A Strep Positive Swab (M2) (Medium Level) | RED-S-70-M2* | VP-S-70-M2 | Request Quote |
| Group A Strep Positive Swab (M1) (Low Level) | RED-S-70-M1* | VP-S-70-M1 | Request Quote |
| Bordetella parapertussis Positive | Coming soon | ||
| Bordetella parapertussis Positive Swab | Coming soon | ||
| Bordetella pertussis Positive | Coming soon | ||
| Bordetella pertussis Positive Swab | Coming soon | ||
| Chlamydophila pneumoniae Positive | Coming soon | ||
| Chlamydophila pneumoniae Positive Swab | Coming soon | ||
| Legionella pneumophila Positive | Coming soon | ||
| Legionella pneumophila Positive Swab | Coming soon | ||
| Mycoplasma pneumoniae Positive | Coming soon | ||
| Mycoplasma pneumoniae Positive Swab | Coming soon | ||
| Streptococcus dysgalactiae Positive | Coming soon | ||
| Streptococcus dysgalactiae Positive Swab | Coming soon | ||
| Multi-Target Products | |||
| Bordetella pertussis and Bordetella parapertussis Positive | Coming soon | ||
| Bordetella pertussis and Bordetella parapertussis Positive Swab | Coming soon | ||
| Chlamydophila pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae Positive | Coming soon | ||
| Chlamydophila pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae Positive Swab | Coming soon | ||
| NEGATIVE PRODUCTS | |||
| Negative Sample | N/A | VP-99-01 | Request Quote |
| Negative Sample (MDx) | N/A | VP-99-M2 | Request Quote |
| SARS-CoV-2 Negative | RED-99-M3 | VP-99-M3 | Request Quote |
| Respiratory Negative Swab (REDx™FLOQ®) Negative Swab (PROCEEDx™FLOQ®) |
RED-S-99-01 | VP-S-99-01 | Request Quote |
| SARS-CoV-2 Negative Swab (REDx™FLOQ®) NAAT Negative Swab (PROCEEDx™FLOQ®) *Formulated with human cells |
RED-S-99-M4 | VP-S-99-M4 | Request Quote |
*Products are registered as Class I medical devices with Health Canada and FDA
Frequently Asked Questions
What pathogens are included in your Respiratory Viral Panel?
The respiratory viral panel includes an extensive SARS-CoV-2 portfolio for nucleic acid and antigen detection assays, covering major variants of concern (B.1.1.7, B.1.351, P.1, B.1.617, B.1.1.529). Other respiratory viral control products include:
Â
- Influenza A, Influenza B, Respiratory Syncytial Virus (low, medium, and high levels)
- Â Adenovirus, Enterovirus, Human Metapneumovirus, Rhinovirus, Parainfluenza Viruses, and Seasonal Coronaviruses
Are your products suitable for use by a clinical diagnostics laboratory?
Yes. Microbix offers two distinct product lines to meet different needs. Our REDx™ IVD products are unassayed controls that support ongoing QC, benchmarking of laboratory testing performance and complete workflow evaluation. Our PROCEEDx™ RUO products are used for assay validation, verification, operator training, and R&D applications.
Are the products formulated with target genes or whole organisms?
Microbix Respiratory External Quality Control products are formulated using native pathogens that have been inactivated to meet biosafety requirements. All products contain the target organism’s whole genome and require extraction. Certain products are also suitable for immunoassays.
Are the products quantified?
Microbix External Quality Control products are unassayed materials. For quantified stocks, refer to the QUANTDx product line.
Testimonials
Proudly Supporting Over 100+ Customers with Leading Diagnostic Solutions
Learn more about how our clients worldwide use Microbix’s product lines to enhance the way they do business.
We considered other external quality controls but selected Microbix QAPs as the best solution to support assay optimization and to significantly simplify QC procedures with minimal to no pipetting steps. Microbix’s technical expertise, product design, performance, and superior customer service are impressive. We look forward to continuing our collaboration.
Robert Martinez, VP of Business Development & Scientific Affairs
We were looking for a set of controls that fully covered the range of high-risk HPV types and Microbix is the only company to have such a portfolio. After an extensive evaluation process, we concluded the performance of Microbix QAPs are exactly what Ulisse needs and the interactions with their team are delightful.
Bruna Marini, COO
MDx testing for HPV improves cervical cancer screening by identifying those at-risk efficiently. Close monitoring of the entire HPV testing workflow is critical to realizing this healthcare goal and Microbix’s HPV QAPs have been selected to support the quality assessment monitoring of the molecular testing process, a vital part of BVO’s quality management system
Dr. Rob Schuurman, National Reference Officer for the Dutch Cervical Cancer Screening Program (BVO)
r-Biopharm is pleased that the program will be delivering world-class diagnostic testing to some of the most remote populations in Australia. It has been a privilege to work with the program’s operational team and Microbix to integrate the use of the best possible test and test-workflow controls into the program
Andreas Simons, Director, Project Management Clinical Diagnostics
We’re pleased to be employing Microbix’s innovative QAPs for this new and important EQA program. Genital ulcers are the cause of a considerable and growing burden of disease that can only be alleviated by way of accurate diagnosis and treatment
Juha Wahlstedt, Sales Director at Labquality
Microbix approached us before the pandemic started, and the relationship developed so easily and quickly that we formalized our collaboration in 2020. Along with their excellent technical capabilities, they have successfully developed relationships with many diagnostics manufacturers around the world. We are pleased that our FLOQSwabs® are their exclusive choice for their growing line of swab formatted QAPs™.
Gaetano Natale, Chief Commercial Officer.
We’ve been using Microbix’s External Quality controls for 3 years specifically from their Respiratory and Sexually Transmitted Infections panels on our instruments. It has helped us ensure accurate and reliable patient results and we’ve been delighted with their performance.
Alfie Zhen Fang, Buyer, Procurement
Your Trusted Source of Respiratory Viral and Bacterial External Quality Controls
Microbix’s easy-to-use swab and liquid formats make our respiratory viral control products a reliable choice for researchers, diagnostic manufacturers, and healthcare professionals.
The respiratory viral and bacterial panel controls include an extensive SARS-CoV-2 portfolio for nucleic acid and antigen detection assays, covering major concern variants (B.1.1.7, B.1.351, P.1, B.1.617, B.1.1.529). Other single-analyte and multiplex respiratory viral molecular controls include:
- Influenza A, Influenza B, Respiratory Syncytial Virus (low, medium, and high levels)
- Group A Strep (low, medium, and high levels)
- Adenovirus, Parainfluenza Viruses, and other common respiratory viruses
Speak to a Customer Service Representative
Let our knowledgeable experts help you secure your products today.
News & Insights from Our Diagnostics Experts
Microbix Reports Results for H1 & Q2 2026
H1 Revenues of $7.6 million and Controlled Net Loss MISSISSAUGA, CANADA, May 14, 2026 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporte…
Microbix Schedules Release of Results for Q2 Fiscal 2026
Microbix announces announces it will be attending and presenting at the 2026 Bloom Burton & Co. Healthcare Investor Conference (the “Conference”) taking place at the Metro Toronto Convention Centre, North B…
Microbix Product Results Being Presented at 2026 PASCV
Microbix announces announces it will be attending and presenting at the 2026 Bloom Burton & Co. Healthcare Investor Conference (the “Conference”) taking place at the Metro Toronto Convention Centre, North B…
